

ASX ANNOUNCEMENT

14 November 2024

Biome Strain Development Program Success


- *Biome* has successfully completed the identification, commercial validation and initial characterisation of the probiotic strain *Lactobacillus plantarum* BMB18
- The strain has been lodged with the German culture bank DSMZ
- Transfer of the intellectual property, BMB18, to Biome will take place in the coming weeks from *Biome's* R&D partner
- This new IP will strengthen *Biome's* advantage in probiotic product development and increase protection from competition

Microbiome health company *Biome Australia Limited* (ASX: BIO) ('Biome' or 'the company') is pleased to provide an update on the biological Intellectual Property (IP) agreement announced to the market on 11 December 2023.

Following the successful preliminary identification, commercial validation, and characterisation of the probiotic strain *Lactobacillus plantarum* BMB18, *Biome* will move into commercialisation. This milestone is a significant step for *Biome* in IP ownership, new product development opportunities and a pipeline for research and development for the coming years. *Biome's* scientific strength is in the understanding of mechanisms of action of specific strains and the commercialisation of novel targeted probiotics. With this understanding, in combination with our own unique strain, our intention is to target further health outcomes that have yet to be approached within the market.

The strain, BMB18, has now been registered and deposited with the international deposit authority Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). The DSMZ is an internationally-recognised microbial culture collection that gathers, maintains and distributes cultures of well-characterised and unique microorganisms, including probiotic strains, for various industries and purposes (1).

As per the agreement terms with one of *Biome's* probiotic research and development partners, the IP will now transfer to *Biome's* ownership and the IP program will now move to external characterisation, to further develop the value and functionality of this exciting new probiotic strain



Further external characterisation of the strain will continue and *Biome* will work through the clinical pipeline to ascertain the best research targets for this strain and inform future condition-specific applications and product formulations. Future research and development budget on BMB18 is not expected to be of material expense. *Biome* will utilise partner laboratories for pre-clinical research and leverage our knowledge on strain mechanisms of actions to carefully derisk any future clinical development programs.

The expectation is that this probiotic strain will further strengthen *Biome's* commercial advantage and the uniqueness of its *Activated Probiotics* products by supporting future novel product development.

This novel strain will provide *Biome* with both an owned probiotic strain and any potential future licensing opportunities. Making it both an asset and potential new revenue stream on *Biome Australia's* balance sheet.

Biome Australia's Managing Director and Founder, Blair Vega Norfolk commented:

"This is a major step forward for Biome in the growth and development of the business with the further ownership of probiotic intellectual property. This new strain, BMB18, is an incredible opportunity for long-term product innovation and diversification into new health areas. As a Biome owned asset we expect to create significant value for the business as we continue our journey in research and development into new areas with probiotic listed medicines"

-ENDS-

Approved for release by the Biome Australia board of directors.

About Biome Australia Limited

Biome Australia develops, licences, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.



Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics[®].

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations

Jo Power

+61 (3) 9017 5800

corporate@biomeaustralia.com

Media enquiries

media@activated.co

Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*



Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.

References:

1. Nelson, Karen E. (2013). Encyclopedia of Metagenomics || Culture Collections in the Study of Microbial Diversity, Importance. , 10.1007/978-1-4614-6418-1(Chapter 741-4), 1-5.
doi:10.1007/978-1-4614-6418-1_741-4

